2016 ASCO Annual Meeting Abstract 8001: Lenalidomide (LEN) Maintenance (MNTC) After High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma (MM): A Meta-Analysis (MA) of Overall Survival (OS)

This large MA demonstrates that LEN MNTC significantly prolonged OS vs CTL post ASCT, including in pts who achieved CR, demonstrating benefit in pts in all response categories.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.